{"id":"e78e7ae607d1","type":"article","url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","title":"CIRCA-DOSE: AF-progressie na cryoablatie versus RF-ablatie","title_en":"Atrial fibrillation progression after cryoablation vs. radiofrequency ablation: the CIRCA-DOSE trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["cryoablatie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad572","source_url":"https://doi.org/10.1093/eurheartj/ehad572","authors":["Jason G Andrade","Marc W Deyell","Paul Khairy","Jean Champagne","Peter Leong-Sit","Paul Novak","Lawrence Sterns","Jean-Francois Roux","John Sapp","Richard Bennett","Matthew Bennett","Nathaniel Hawkins","Prashanthan Sanders","Laurent Macle"],"significance":6,"published":"2024-02-16","source_date":"2024-02-16","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/katheterablatie-af/"],"congress":"","summary_en":"The CIRCA-DOSE trial showed that AF progression from paroxysmal to persistent is comparable between cryoballoon and radiofrequency ablation, suggesting that the energy source does not significantly influence the natural history of AF.","created":"2026-07-03T10:30:47Z","updated":"2026-07-03T13:29:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De CIRCA-DOSE-trial toonde dat de progressie van paroxysmaal naar persisterend AF vergelijkbaar was na cryoballon- en RF-ablatie. Beide technieken vertragen de AF-progressie even effectief, wat de keuze vrijlaat.","abstract_original":"BACKGROUND AND AIMS: Atrial fibrillation (AF) is a chronic progressive disorder. Persistent forms of AF are associated with increased rates of thromboembolism, heart failure, and death. Catheter ablation modifies the pathogenic mechanism of AF progression. No randomized studies have evaluated the impact of the ablation energy on progression to persistent atrial tachyarrhythmia. METHODS: Three hundred forty-six patients with drug-refractory paroxysmal AF were enrolled and randomly assigned to contact-force-guided RF ablation (CF-RF ablation, 115), 4 min cryoballoon ablation (CRYO-4, 115), or 2 min cryoballoon ablation (CRYO-2, 116). Implantable cardiac monitors placed at study entry were used for follow-up. The main outcome was the first episode of persistent atrial tachyarrhythmia. Secondary outcomes included atrial tachyarrhythmia recurrence and arrhythmia burden on the implantable monitor. RESULTS: At a median of 944.0 (interquartile range [IQR], 612.5-1104) days, 0 of 115 patients (0.0%) randomly assigned to CF-RF, 8 of 115 patients (7.0%) assigned to CRYO-4, and 5 of 116 patients (4.3%) assigned to CRYO-2 experienced an episode of persistent atrial tachyarrhythmia (P = .03). A documented recurrence of any atrial tachyarrhythmia ≥30 s occurred in 56.5%, 53.9%, and 62.9% of those randomized to CF-RF, CRYO-4, and CRYO-2, respectively; P = .65. Compared with that of the pre-ablation monitoring period, AF burden was reduced by a median of 99.5% (IQR 94.0%, 100.0%) with CF-RF, 99.9% (IQR 93.3%-100.0%) with CRYO-4, and 99.1%% (IQR 87.0%-100.0%) with CRYO-2 (P = .38). CONCLUSIONS: Catheter ablation of paroxysmal AF using radiofrequency energy was associated with fewer patients developing persistent AF on follow-up."}